Cover Image

A cost-effectiveness analysis of the 13-valent pneumococcal conjugated vaccine and the 23-valent pneumococcal polysaccharide vaccine among Thai older adult

IntroductionThis study aims to assess the economic impact of introducing the 13-valent pneumococcal conjugate vaccine (PCV13) and 23-valent pneumococcal polysaccharide vaccine (PPSV23) to Thai older adult aged ≥ 65 years who are healthy or with chronic health conditions and immunocompromised condit...

Full description

Saved in:

Bibliographic Details
Main Authors:	Thundon Ngamprasertchai (Author), Chayanis Kositamongkol (Author), Saranath Lawpoolsri (Author), Pinyo Rattanaumpawan (Author), Viravarn Luvira (Author), Piriyaporn Chongtrakool (Author), Jaranit Kaewkungwal (Author), Kulkanya Chokephaibulkit (Author), Pochamana Phisalprapa (Author)
Format:	Book
Published:	Frontiers Media S.A., 2023-06-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Pneumococcal carriage among high-risk adults in a country with nonmandatory pneumococcal vaccination during the coronavirus disease 2019 pandemic
by: Thundon Ngamprasertchai, et al.
Published: (2023)

Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine compared to 13-valent pneumococcal conjugate vaccine in adults ≥65 years of age previously vaccinated with 23-valent pneumococcal polysaccharide vaccine
by: James T. Peterson, et al.
Published: (2019)

Cost-effectiveness of the 13-valent pneumococcal conjugate vaccine in adults in Portugal versus "no vaccination" and versus vaccination with the 23-valent pneumococcal polysaccharide vaccine
by: Miguel Gouveia, et al.
Published: (2019)

13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE
by: V. K. Tatochenko, et al.
Published: (2012)

Cost-effectiveness analysis of 13-valent pneumococcal conjugate vaccine versus 23-valent pneumococcal polysaccharide vaccine in an adult population in South Korea
by: Min-Joo Choi, et al.
Published: (2018)

Persistence of antibodies 1 year after sequential administration of the 13-valent pneumococcal conjugate vaccine and the 23-valent pneumococcal polysaccharide vaccine in adults
by: Beate Schmoele-Thoma, et al.
Published: (2019)

13-valent pneumococcal conjugate vaccine in Africa
by: Robert Cohen, et al.
Published: (2017)

Health and economic outcomes of 20-valent pneumococcal conjugate vaccine compared to 15-valent pneumococcal conjugate vaccine strategies for adults in Greece
by: George Gourzoulidis, et al.
Published: (2023)

INTERNATIONAL EXPERIENCE WITH 7-VALENT PNEUMOCOCCAL CONJUGATE VACCINE
by: David G. McIntosh
Published: (2009)

INTERNATIONAL EXPERIENCE WITH 7-VALENT PNEUMOCOCCAL CONJUGATE VACCINE
by: David G. McIntosh
Published: (2009)

Pneumococcal conjugate 7-valent vacciPNEUMOCOCCAL CONJUGATE 7-VALENT VACCINE IN CHILDREN. REGIONAL EXPERIENCEne in children. Regional experience
by: N. L. Chernaya, et al.
Published: (2012)

PNEUMOCOCCAL INFECTION VACCINAL PREVENTION EFFICACY IN CHILDREN USING PNEUMOCOCCAL CONJUGATED 7-VALENT VACCINE
by: N. L. Chernaya, et al.
Published: (2013)

Cost-effectiveness of a national immunization program with the 13-valent pneumococcal conjugate vaccine compared with the 10-valent pneumococcal conjugate vaccine in South Korea
by: Hye-Young Kim, et al.
Published: (2021)

Modeling the sustained use of the 13-valent pneumococcal conjugate vaccine compared to switching to the 10-valent vaccine in Mexico
by: Matthew Wasserman, et al.
Published: (2019)

Cost-effectiveness analysis of replacing the 10-valent pneumococcal conjugate vaccine (PCV10) with the 13-valent pneumococcal conjugate vaccine (PCV13) in Brazil infants
by: Johnna Perdrizet, et al.
Published: (2021)

Higher valent Pneumococcal Conjugate Vaccines: is it a roller coaster?
by: Godwin Oligbu
Published: (2020)

RECOMMENDATION ON THE 7-VALENT PNEUMOCOCCAL CONJUGATED VACCINE AMONG CHILDREN
by: M.V. Fedoseenko, et al.
Published: (2009)

RECOMMENDATION ON THE 7-VALENT PNEUMOCOCCAL CONJUGATED VACCINE AMONG CHILDREN
by: M.V. Fedoseenko, et al.
Published: (2009)

Effectiveness and practical uses of 23-valent pneumococcal polysaccharide vaccine in healthy and special populations
by: Yang Wang, et al.
Published: (2018)

Pneumococcal meningitis: epidemiological profile pre- and post-introduction of the pneumococcal 10-valent conjugate vaccine
by: Tatiane E. Hirose, et al.
Published: (2015)

Pneumococcal meningitis: epidemiological profile pre‐ and post‐introduction of the pneumococcal 10‐valent conjugate vaccine
by: Tatiane E. Hirose, et al.
Published: (2015)

Pneumococcal meningitis: epidemiological profile pre- and post-introduction of the pneumococcal 10-valent conjugate vaccine
by: Tatiane E. Hirose, et al.
Published: (2015)

The burden of carbapenem-resistant Enterobacterales infection in a large Thai tertiary care hospital
by: Watcharaphon Tangsawad, et al.
Published: (2022)

The impact of 10-valent pneumococcal vaccine introduction on invasive disease in Fiji
by: R. Reyburn, et al.
Published: (2022)

Clinical Efficacy of Pneumococcal Conjugate 13-valent Vaccine in Young Children
by: S. M. Kharit, et al.
Published: (2016)

Antibody response to the 23-valent pneumococcal polysaccharide vaccine after conjugate vaccine in patients with chronic lymphocytic leukemia
by: Vesa Lindström, et al.
Published: (2019)

Impact of 10-valent pneumococcal conjugate vaccine on pneumococcal meningitis in children up to two years of age in Brazil
by: Indianara Maria Grando, et al.
Published: (2015)

Efficacy of usage of pneumococcal 7-valent vaccine in prophylaxis of pneumococcal infection in Novosibirsk children from risk groups
by: O. A. Beletskaya, et al.
Published: (2013)

INCIDENCE OF PNEUMOCOCCAL INFECTION IN THE WESTERN EUROPEAN COUNTRIES. INTERNATIONAL EXPERIENCE IN USING SEVEN-VALENT PNEUMOCOCCAL CONJUGATED VACCINE
by: article editorial
Published: (2008)

PNEUMOCOCCAL INFECTION. IMMUNIZATION BY A 7-VALENT CONJUGATED PNEUMOCOCCAL VACCINE OF CHILDREN BORN TO HIV-POSITIVE WOMEN
by: L.Yu Afoninа, et al.
Published: (2011)

INCIDENCE OF PNEUMOCOCCAL INFECTION IN THE WESTERN EUROPEAN COUNTRIES. INTERNATIONAL EXPERIENCE IN USING SEVEN-VALENT PNEUMOCOCCAL CONJUGATED VACCINE
by: article editorial
Published: (2008)

PNEUMOCOCCAL INFECTION. IMMUNIZATION BY A 7-VALENT CONJUGATED PNEUMOCOCCAL VACCINE OF CHILDREN BORN TO HIV-POSITIVE WOMEN
by: L.Yu Afoninа, et al.
Published: (2011)

EXPERIENCE OF USE OF PNEUMOCOCCAL CONJUGATED 7-VALENT VACCINE IN SOME REGIONS OF RUSSIA
by: A.A. Ruleva, et al.
Published: (2010)

EXPERIENCE OF USE OF PNEUMOCOCCAL CONJUGATED 7-VALENT VACCINE IN SOME REGIONS OF RUSSIA
by: A.A. Ruleva, et al.
Published: (2010)

Economic evaluations of 13-valent pneumococcal conjugate vaccine: a systematic review
by: Yuanze Du, et al.
Published: (2023)

Coadministration of 13-valent pneumococcal conjugate and quadrivalent inactivated influenza vaccines in adults previously immunized with polysaccharide pneumococcal vaccine 23: a randomized clinical trial
by: Allison R. Thompson, et al.
Published: (2019)

Immunogenicity and safety after the third vaccination with the 23-valent pneumococcal polysaccharide vaccine in elderly patients with chronic lung disease
by: Nobuharu Ohshima, et al.
Published: (2020)

Response to article by Johnna Perdrizet et al.,"Cost-effectiveness analysis of replacing the 10-valent pneumococcal conjugate vaccine (PCV10) with the 13-valent pneumococcal conjugate vaccine (PCV13) in Brazil infants"
by: Jorge A. Gómez, et al.
Published: (2022)

Analysis of 13-valent pneumococcal polysaccharide conjugate vaccine among children born in Hangzhou from 2017 to 2021
by: Xinren Che, et al.
Published: (2023)

Safety of the 15-valent pneumococcal conjugate vaccine: A phase I clinical trial
by: Lu-Lu Pan, et al.
Published: (2022)